Adviye Ergul to Matrix Metalloproteinase 9
This is a "connection" page, showing publications Adviye Ergul has written about Matrix Metalloproteinase 9.
Connection Strength
0.529
-
Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R435-41.
Score: 0.233
-
Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Mar 15; 304(6):H806-15.
Score: 0.096
-
Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke. 2011 Sep; 42(9):2633-5.
Score: 0.087
-
Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens. 2004 Sep; 17(9):775-82.
Score: 0.054
-
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res. 2013 Dec; 38(12):2668-77.
Score: 0.025
-
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke. 2009 Sep; 40(9):3028-33.
Score: 0.019
-
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17; 7:56.
Score: 0.015